|
Perindopril publications
 Morgan T, Anderson A. Duration of antihypertensive
effect of perindopril (P), enalapril (E) and captopril (C). Hypertension.
1993;21:568.
Kool MJ, Lustermans FA, Breed JG, Struyker Boudier HA, Hoaks AP, Reneman
RS and Van Bortel LM. The influence of perindopril and the diuretic combination
amiloride+hydrochlorothiazide on the vessel wall properties of large arteries
in hypertensive patients. J Hypertens. 1995;13:839-848.
Fogari R, Zoppi A, Lazzari P, et al. ACE inhibition but not angiotensin
II antagonism reduces plasma fibrinogen and insulin resistance in overweight
hypertensive patients. J Cardiovasc Pharmacol. 1998;32:616-620.
Barthels GL, et al. Acute anti-ischemic effects of perindoprilat in men
with coronary artery disease and their relation with left ventricular function.
Am. J. Cardiol. 1999;83: 332-336.
 Schwartzkopff B, et al. Repair of coronary arterioles after treatment with
perindopril in hypertensive heart disease. Hypertension. 2000;36:220-225.
PROGRESS Collaborative Group. Randomised trial of a perindopril- based
blood-pressure regimen among 6105 patients with prior stroke or transient
ischaemic attack. Lancet. 2001;358:1033-1041.
Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindopril effects
on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive
type 2 diabetic patients. Am J Hypertens. 2002;15:316-320.
Lau CP, Tse HF, Ng W, et al. Comparison of perindopril versus captopril
for treatment of acute myocardial infarction. Am J Cardiol. 2002;89:150-154.
Shimokawa H, et al. Long-term treatment with perindopril ameliorates dobutamine-induced
myocardial ischemia in patients with coronary artery disease. Jpn J.
Pharmacol.
2002;88:100-107.
Matsumoto T, Minai K, Horie H et al. Angiotensin-converting enzyme inhibition
but not angiotensin II type 1 receptor antagonism augments coronary release
of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol.
2003;41:1373-1379.
PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril
and indapamide on dementia and cognitive decline in patients with cerebrovascular
disease. Arch Intern Med. 2003;163:1069-1075.
Additional ACE inhibitors publications
The
CONSENSUS Trial Study Group. Effects of enalapril on mortality
in severe congestive heart failure. N Engl J Med.
1987;316:1429–1435. CONSENSUS
The
SOLVD investigators. Effects of enalapril
on survival in patients with reduced left ventricular
ejection fractions
and congestive heart failure. N Engl
J Med. 1991;325:293–302.
SOLVD-treatment study. Carson
P, Johnson G, Fletcher R, Cohn J. Mild systolic dysfunction
in heart failure (left ventricular ejection
fraction >35%):
baseline characteristics, prognosis
and response to therapy in the Vasodilator in Heart Failure
Trials (V-HeFT).
J Am Coll Cardiol.
1996;27:642-649. V-HeFT
Cohn JN, Johnson
G, Ziesche S, Cobb F, Francis G, Tristani F, Smith
R, Dunkman WB, Loeb H, Wong M, et al. A comparison
of enalapril with
hydralazine-isosorbide dinitrate in the treatment
of chronic congestive
heart failure. N Engl J Med. 1991;325:303-310.
V-HeFT II The SOLVD Investigators.Effect
of enalapril on mortality and
the development of
heart failure in asymptomatic patients
with educed left
ventricular ejection fractions.N
Engl J Med. 1992;327:685-691.
SOLVD-prevention study Yusuf S, Pepine CJ, Garces
C,et al.
Effect of enalapril
on myocardial infarction and unstable angina
in
patients with low
ejection fractions. Lancet 1992;340:1173-1178. SOLVD Pfeffer
MA, Braunwald E,Moyé LA,et al. On behalf
of the SAVE
investigators.
Effect of captopril
on mortality and morbidity in patients with
left ventricular
dysfunction after myocardial infarction: results
of the
Survival and
Ventricular Enlargement trial. N Engl J Med.
1992;327:669-677. SAVE The Acute Infarction
Ramipril Efficacy
(AIRE) Study
Investigators. Effect
of ramipril on mortality and morbidity of
survivors of
acute myocardial
infarction with clinical
evidence of heart failure.
Lancet 1993;342:821-828.
AIRE Køber L, Torp-Pedersen
C,Carlsen JE,et al. For the Trandolapril Cardiac Evaluation
(TRACE) Study Group.
A clinical trial
of the angiotensin-converting –enzyme inhibitor
trandolapril in
patients
with
left ventricular
dysfunction after myocardial infarction. N
Engl
J
Med.
1995;333:1670-1676.
TRACE Ambrosioni E, Borghi C,
Magnani B.
The effect of the
angiotensin-converting-enzyme inhibitor zofenopril on mortality
and morbidity after
anterior myocardial infarction. The Survival
of Myocardial Infarction
Long-Term Evaluation (SMILE) Study Investigators. N Engl
J Med. 1995;332:80-85. SMILE Swedberg K, Held P, Kjekshus
J, Rasmussen
K, Ryden
L, Wedel H. Effects of the early administration of enalapril on mortality in
patients
with acute myocardial infarction. Results
of the Cooperative
New Scandinavian Enalapril Survival Study II (CONSENSUS
II).
N Engl J Med. 1992;327:678-684. CONSENSUS
II ISIS-4: a
randomised
factorial trial assessing
early oral captopril, oral mononitrate, and intravenous
magnesium sulphate in 58,050
patients
with suspected acute myocardial
infarction.
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.
Lancet.
1995;345:669-685. ISIS-4 GISSI-3:
effects
of lisinopril and
transdermal glyceryl trinitrate singly and together on
6-week mortality and ventricular function
after acute
myocardial infarction.
Gruppo
Italiano per lo
Studio della
Sopravvivenza nell'infarto
Miocardico. Lancet. 1994;343:1115-1122. GISSI-3 Pitt
B,
O’Neill B, Feldman R et al. QUIET Study Group.
The Quinapril
Ischemic
Event Trial
(QUIET): evaluation of chronic ACE inhibitor therapy
in patients with
ischemic heart disease
and preserved left ventricular function. Am J Cardiol.
2001;87:1058-1063.
QUIET The Heart Outcomes Prevention
Evaluation Study Investigators.
Effects of an angiotensin-converting-enzyme
inhibitor, ramipril, on cardiovascular
events
in high-risk patients.
N Engl J Med. 2000;342:145-153.
HOPE Pfeffer
MA, Domanski
M, Rosenberg Y, et
al. Prevention of
events with angiotensin-converting
anzyme inhibitor
(The
PEACE study design).
Am
J Cardiol 1998;82:25H–30H.
PEACE Does the new angiotensin
converting enzyme inhibitor
cilazapril prevent
restenosis after percutaneous transluminal coronary angioplasty?
Results
of the MERCATOR
study: a multicenter, randomized,
double-blind placebo-controlled
trial. Multicenter European Research Trial
with Cilazapril after Angioplasty to
Prevent Transluminal
Coronary Obstruction and Restenosis (MERCATOR) Study
Group.
Circulation.
1992;86:100-110.
MERCATOR Faxon DP. Effect of high dose angiotensin-converting
enzyme inhibition on restenosis: final results of the
MARCATOR Study, a multicenter,
double-blind, placebo-controlled trial
of cilazapril. The Multicenter American Research Trial
With Cilazapril After
Angioplasty
to Prevent Transluminal Coronary Obstruction and
Restenosis (MARCATOR) Study Group. J Am Coll Cardiol.
1995;25:362-369. MARCATOR
|
ESC 2003 Hotline - video